ISPOR CEO Named a 2018 PharmaVOICE 100 Honoree

Published Aug 6, 2018
Nancy S. Berg Recognized as a Transformational Commander and Chief Lawrenceville, NJ, USA—August 6, 2018—ISPOR, the professional society for health economics and outcomes research, announced that CEO and Executive Director Nancy S. Berg has been named a 2018 PharmaVOICE 100 honoree by PharmaVOICE magazine. She has been recognized as a transformational leader in the Commander and Chief category. In 2014, Ms Berg moved into the role of CEO for ISPOR, the leading global scientific and educational organization for HEOR. Since that time, she has worked closely with ISPOR’s Board of Directors to strengthen the Society and further its mission to advance HEOR excellence to improve decision making globally. Ms Berg has initiated a number of key strategic initiatives during her tenure at ISPOR. After hiring the Society’s first ever Chief Science Officer, ISPOR began initiatives on value assessment frameworks and a jointly led initiative on real-world evidence (in partnership with the International Society for Pharmacoepidemiology). The Society launched its Health Technology Assessment Central, an online source that is a comprehensive repository of resources and tools to support health technology assessment. ISPOR is currently launching phase I of its comprehensive information technology (IT) initiative. The IT project includes a number of critical, integrated systems to better serve its global membership, such as an association management system and new website. Other key programs have included the initiation of a new Patient Council, an HEOR Competencies Framework™, and a Women in HEOR Initiative. The PharmaVOICE 100 was established fourteen years ago by PharmaVOICE magazine and is an annual list of inspirational individuals recognized for their positive contributions to the life sciences industry.

###

  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg ABOUT PharmaVOICE Published monthly, with the combined July/August PharmaVOICE 100 and November/December Year in Preview issues, PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of the executives who are shaping the direction of the dynamic and multifaceted life-sciences industry. PharmaVOICE reaches more than 46,000 BPA qualified subscribers and 60,000 users with its digital edition.

Related Stories

Generative AI Set to Reshape Health Technology Assessment, ISPOR Report Finds

Feb 11, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of an ISPOR Working Group Report that provides an introduction to the uses of generative artificial intelligence (AI) in health technology assessment (HTA).

ISPOR Announces New Chief Financial Officer

Feb 4, 2025

ISPOR announces that Kate Tarpey has been appointed to serve as the Society’s Chief Financial Officer.

ISPOR Tackles Health Disparities with New Research Primer

Jan 22, 2025

ISPOR announced today the publication of a report from the ISPOR Health Equity Research Special Interest Group intended to establish key concepts for conducting health equity research that enables investigators to examine—and ultimately reduce—unfair social inequities in health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×